ESMO 2022 Conference Coverage
ESMO 2022 on the Phase 3 HIMALAYA Study: Impact of Viral Aetiology of Tremelimumab + Durvalumab in Unresectable HCC
By
ESMO 2022 Conference Coverage
FEATURING
Stephen L. Chan
By
ESMO 2022 Conference Coverage
FEATURING
Stephen L. Chan
Login to view comments.
Click here to Login
GI